Categories: News

Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024

BELGRADE, MO / ACCESSWIRE / May 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of the financial markets on Wednesday, May 15, 2024.

Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Wednesday, May 15 at 4:30 PM ET to review results.

Conference Details:
Conference Date: Wednesday, May 15, 2024
Conference Time: 4:30 PM ET
Conference dial-in: 877-545-0523
International dial-in: 973-528-0016
Passcode: 693614
Conference Call Name: Xtant Medical Q1 2024 Financial Results
Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/50597

Following the live call, a replay will be available on the Company’s website, https://xtantmedical.com/, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (https://xtantmedical.com/) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Investor Relations Contact

Brett Maas • Managing Partner, Hayden IR
brett@haydenir.com • (646) 536-7331

SOURCE: Xtant Medical Holdings, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida

New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B…

54 minutes ago

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

54 minutes ago

TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in…

3 hours ago

Building a Healthier Future Together: Strengthening Cancer Care Across Africa Through Partnership

NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Originally published on Bristol Myers…

3 hours ago

Restart Life Announces Food Technology and Research Studies

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

5 hours ago